11/26
10:30 am
mbrx
Moleculin Announces Reverse Stock Split [Yahoo! Finance]
Medium
Report
Moleculin Announces Reverse Stock Split [Yahoo! Finance]
11/26
09:15 am
mbrx
Moleculin to Participate in the Virtual Investor Closing Bell Series
Low
Report
Moleculin to Participate in the Virtual Investor Closing Bell Series
11/26
09:08 am
mbrx
Moleculin to execute 1-for-25 reverse stock split [Seeking Alpha]
Medium
Report
Moleculin to execute 1-for-25 reverse stock split [Seeking Alpha]
11/26
09:00 am
mbrx
Moleculin Announces Reverse Stock Split
High
Report
Moleculin Announces Reverse Stock Split
11/13
08:51 am
mbrx
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented [Yahoo! Finance]
Low
Report
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented [Yahoo! Finance]
11/13
08:36 am
mbrx
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Medium
Report
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
11/12
09:01 am
mbrx
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill [Yahoo! Finance]
Low
Report
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill [Yahoo! Finance]
11/12
08:37 am
mbrx
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
Low
Report
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
10/30
08:40 am
mbrx
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
Medium
Report
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
10/29
08:35 am
mbrx
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
Low
Report
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
10/25
12:09 pm
mbrx
Moleculin Biotech (NASDAQ:MBRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Moleculin Biotech (NASDAQ:MBRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/23
08:00 am
mbrx
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
Medium
Report
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
9/26
09:10 am
mbrx
Moleculin Biotech announces issuance of Canadian patent covering Annamycin [Yahoo! Finance]
Medium
Report
Moleculin Biotech announces issuance of Canadian patent covering Annamycin [Yahoo! Finance]
9/25
09:19 am
mbrx
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin [Yahoo! Finance]
Low
Report
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin [Yahoo! Finance]
9/25
08:35 am
mbrx
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
Low
Report
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
9/19
05:28 pm
mbrx
Moleculin Biotech files to sell 64.86M shares of common stock by selling shareholder [Seeking Alpha]
Low
Report
Moleculin Biotech files to sell 64.86M shares of common stock by selling shareholder [Seeking Alpha]
9/10
08:00 am
mbrx
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Medium
Report
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
9/9
09:11 am
mbrx
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial [Yahoo! Finance]
Low
Report
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial [Yahoo! Finance]
9/9
08:45 am
mbrx
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
Medium
Report
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
9/8
08:30 am
mbrx
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Medium
Report
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia